Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

xilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2009 and in Auxilium's Quarterly Report on Form 10-Q for the period ended September 30, 2010 which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.

AUXILIUM PHARMACEUTICALS, INC.Condensed Consolidated Statement of Operations(In thousands, except share and per share amounts)(Unaudited)Three Months Ended December 31,Twelve Months Ended December 31,2010200920102009Net revenues

$
,830$
48,027$   211,429$   164,039Operating expenses*:Cost of goods sold

17,16510,41649,72537,077Research and development

13,95411,37548,00551,398Selling, general and administrative

47,00838,711164,675129,181Total operating expenses

78,12760,502262,405217,656Loss from operations

(16,297)(12,475)(50,976)(53,617)Interest income (expense), net

(99)(38)(255)160Loss before income taxes

(16,396)(12,513)(51,231)(53,457)Provision for income taxes

-(614)--Net loss

$
(16,396)$
(11,899)$
(51,231)$
(53,457)Basic and diluted net loss percommon share

$
(0.34)$
(0.25)$
(1.08)$
(1.22)Weighted average common sharesoutstanding

47,666,40647,001,77947,426,84943,650,775*includes the following amountsof stock-based compensation expense:Cost of goods sold

$
46$
-$
55$
-Research and development

1,2831,0272,6985,048Selling, general and administrative

4,6203,33615,10912,852AUXILIUM PHARMACEUTICALS, INC.Selected Consolidated Balance Sheet Data(In thousands)(Unaudited)December 31,December 31,20102009Cash and cash equivalents'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... 2015 Adaptive Biotechnologies announced today that ... Board of Director as Chair of the Audit Committee. ... Chad oversees all finance, treasury and accounting functions. Since ... finance, treasury and accounting functions, and led the finance ... 2013, he was named Puget Sound Business Journal,s CFO ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
(Date:3/3/2015)... 3, 2015 Fried, Frank, Harris, Shriver & ... has joined the Firm as a partner in ... New York office. Mr. Lewis concentrates ... well as other intellectual property and general litigation. A ... represents both plaintiffs and defendants in a range of ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... first quarter 2008 stock ... repurchase program, BOSTON, April 30 ... image and information management,solutions, today reported unaudited financial results for the first ... ), Q1 Financial Highlights, Revenue: Total revenues for the ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ), a ... financial results for Q1 2008. Q1 2008,revenues were ... 2007., Q1 2008 revenues increased 5% in ... in its vascular category, while general,surgery revenues decreased ...
... New Step in the Company,s Global Branding Strategy, ... today announced the full integration of its Riedel-de ... May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., "We have ... and,services," said Josef Zihlmann, Global Vice President of ...
Cached Biology Technology:AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 3AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 4AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 5AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 6AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 7AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 8AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 9AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 10AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 11LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 3LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 4LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 5LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 6LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 7LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 8LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 9LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 10LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 11Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... extend a family should avoid using the cholesterol-lowering drugs ... that women who are pregnant should stop taking statins ... cholesterol is essential for normal fetal development. Indeed, ... in children of pregnant women using statins suggested that ...
... for HIV patients may be the best way of treating hepatitis ... A study of a protein called p7, has revealed that differences ... - known as genotypes - alter the sensitivity of the ... protein assists the spread of HCV around the body ...
... researchers from Penn State University and the University of Chicago ... particular virus, called N4, injects an unusual substance -- an ... bacterial cell. The results, which are published in the ... to improved understanding of the infection strategies used by viruses ...
Cached Biology News:Statin warning for pregnant women 2Leeds research points to new therapy for hepatitis C treatment 2Properties of unusual virus revealed in research 2Properties of unusual virus revealed in research 3
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
...
Biology Products: